Sales of 63,223 million yen, year-over-year change of \u25b33.1%. Operating income 2,632 million yen (up 11.2%), Ordinary income 2,440 million yen (\u25b34.4%), Net income attributable to owners of the parent 1,988 million yen (up 439.1%). Full-year projections: sales 64,000 million yen, operating income 3,000 million yen, net income 2,200 million yen. Segments comprise BtoB, BtoC, and Biomedicals. Continued expansion of research and development investments and new products and overseas deployment. A financial results briefing is planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2929","jir_company_name":"Pharm Foods Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2929-20260911-01.pdf","jir_short_summary":"Sales of 63,223 million yen, year-over-year change of \u25b33.1%. Operating income 2,632 million yen (up 11.2%), Ordinary income 2,440 million yen (\u25b34.4%), Net income attributable to owners of the parent 1,988 million yen (up 439.1%). Full-year projections: sales 64,000 million yen, operating income 3,000 million yen, net income 2,200 million yen. Segments comprise BtoB, BtoC, and Biomedicals. Continued expansion of research and development investments and new products and overseas deployment. A financial results briefing is planned.","jir_summary":"### Overview of Results\nUnder the Mid-Term Management Plan 2026, the Group is promoting the 1K Value Creation project. Development of a new electrode material following Ovoveil, an eggshell membrane material, continues in the drug discovery space with cancer-related antibodies and peptide drugs. New products include expansion of the Neumo series and deployment of Neumo D, plus enhanced sales of Pharma Gaba in North America and Thailand. The financial summary reports sales of 63,223 million yen, operating income of 2,632 million yen, and net income attributable to owners of the parent of 1,988 million yen, marking a substantial increase in net income, while ordinary income declined year over year. R&D investment reached 1,858 million yen and advertising expense was 33,917 million yen, down from the previous period. Full-year guidance projects sales of 64,000 million yen, operating income of 3,000 million yen, and net income of 2,200 million yen.\n\n### Trends by Segment and Financial Impact\nBtoB remains steady, including functional materials, CMO, and CHC. BtoC sales of pharmaceuticals, quasi-drug products, cosmetics, and supplements are solid, with new products such as Neumo hair-growth products contributing. The Biomedicals segment includes antibody drugs and proteome analysis support. Overall, new product launches and overseas expansion drive profit growth, while ordinary income shows a downward trend.","jir_financial_highlights":"Sales: 63,223 million yen (YoY \u25b33.1%)\nOperating income: 2,632 million yen (YoY+11.2%)\nOrdinary income: 2,440 million yen (YoY \u25b34.4%)\nNet income attributable to owners of the parent: 1,988 million yen (YoY +439.1%)\nNet assets per share: 453.35 yen (YoY Unknown (with comparative information))","jir_category":"","jir_hashtags":"#PharmFoods, #Earnings, #MidTermPlan2026","jir_key_figures":"Sales: 63,223 million yen\uff08YoY\u25b33.1\uff05\uff09\nOperating income: 2,632 million yen\uff08YoY+11.2\uff05\uff09\nNet income attributable to owners of the parent: 1,988 million yen\uff08YoY+439.1\uff05\uff09","jir_meta_title":"Pharm Foods Financial Summary for FY2026 July\u671f | Sales 63,223 million yen \/ Net income 1,988 million yen","jir_meta_description":"Pharm Foods Financial Summary for the FY2026 July\u671f. Sales 63,223 million yen, Operating income 2,632 million yen, Net income 1,988 million yen. Progress of the Mid-Term Plan \u201c1K Value Creation Project,\u201d including eggshell membrane materials, drug discovery, new products, and overseas expansion as key factors.","jir_og_title":"Pharm Foods Financial Summary \u2014 Sales of 63,223 million yen and Net Income Increase","jir_og_description":"Pharm Foods Financial Summary for FY2026 July\u671f. Pushing new products and overseas expansion, with a substantial rise in net income. Progress of the mid-term plan disclosed.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\u5e747\u6708\u671f\\\",\\\"2026\u5e747\u6708\u671f\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales\\\",\\\"data\\\":[65260,63223]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\u5e747\u6708\u671f\\\",\\\"2026\u5e747\u6708\u671f\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating income\\\",\\\"data\\\":[2367,2632]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\u5e747\u6708\u671f\\\",\\\"2026\u5e747\u6708\u671f\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net income attributable to owners of the parent\\\",\\\"data\\\":[368,1988]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"BtoB\\\",\\\"BtoC\\\",\\\"Biomedicals\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales\\\",\\\"data\\\":[7471,55368,350]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profitability\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"BtoB\\\",\\\"BtoC\\\",\\\"Biomedicals\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Segment Profit\\\",\\\"data\\\":[125? , 4481, -838]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Forecast vs Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Actual\\\",\\\"Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales\\\",\\\"data\\\":[63223,64000]},{\\\"label\\\":\\\"Operating income\\\",\\\"data\\\":[2632,3000]}]},\\\"options\\\":{}}\"}]","ir_related_company":57923,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-112559","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n